Background and study aims: The introduction of self-expandable metal stents has offered a promising alternative for palliation of malignant left-sided colonic obstruction. This randomized clinical trial aimed to assess whether a nonsurgical policy, with endoluminal stenting, is superior to surgical treatment in patients with stage IV left-sided colorectal cancer and imminent obstruction.Patients and methods: Patients with incurable left-sided colorectal cancer who fulfilled the study criteria were randomly assigned to nonsurgical or surgical treatment. The primary outcome measure was survival in good health out of hospital (World Health Organization performance scores 0 or 1).Results: A high number of serious adverse events in the nonsurgical arm led to premature closure of the trial. Ten patients were allocated to surgical treatment and 11 patients to nonsurgical palliation. The median survival in good health out of hospital during the first year was 56 days (interquartile range 7.5 - 338.5 days) in the surgical arm vs. 38 days (interquartile range 5.25 - 288.75 days) in the nonsurgical arm (P = 0.68). Eleven adverse events (six perforations) occurred in the nonsurgical arm vs. one adverse event in the surgical arm (P < 0.001). Of the six perforations, two were stent-related because they occurred at the proximal edge of the stent by erosion through a normal colon wall; one was probably stent-related (it was located in the region of the proximal half of the stent); one was a colon blowout; and two were late tumor perforations in patients on chemotherapy.Conclusions: The unexpected high rate of perforation in the nonsurgical arm might be specifically WallFlex-related or enteral stent-related in patients on chemotherapy and warrants attention.
References
1
Parkin D M, Bray F, Ferlay J, Pisani P.
Global cancer statistics, 2002.
CA Cancer J Clin.
2005;
55
74-108
2 CCCnet. Comprehensive Cancer Centers 2005 .Available from: http://www.ikcnet.nl/cijfers/index.php
3
Harris G J, Senagore A J, Lavery I C, Fazio V W.
The management of neoplastic colorectal obstruction with colonic endoluminal stenting devices.
Am J Surg.
2001;
181
499-506
4
Allen-Mersh T G, Earlam S, Fordy C. et al .
Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases.
aLancet.
1994;
344
1255-1260
5
Cunningham D, Pyrhonen S, James R D. et al .
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.
Lancet.
1998;
352
1413-1418
6
Meyerhardt J A, Mayer R J.
Systemic therapy for colorectal cancer.
N Engl J Med.
2005;
352
476-487
7
Scheithauer W, Rosen H, Kornek G V. et al .
Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.
BMJ.
1993;
306
752-755
8
Smyth J F, Hardcastle J D, Denton G. et al .
Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer.
Ann Oncol.
1995;
6
948-949
9
Dohmoto M, Rupp K D, Hohlbach G.
Endoscopically-implanted prosthesis in rectal carcinoma [in German, no abstract].
Dtsch Med Wochenschr.
1990;
115
915
10
Tejero E, Mainar A, Fernandez L. et al .
New procedure for the treatment of colorectal neoplastic obstructions.
Dis Colon Rectum.
1994;
37
1158-1159
11
Sebastian S, Johnston S, Geoghegan T. et al .
Pooled analysis of the efficacy and safety of self-expanding metal stenting in malignant colorectal obstruction.
Am J Gastroenterol.
2004;
99
2051-2057
12
Khot U P, Lang A W, Murali K, Parker M C.
Systematic review of the efficacy and safety of colorectal stents.
Br J Surg.
2002;
89
1096-1102
13
Johnson R, Marsh R, Corson J, Seymour K.
A comparison of two methods of palliation of large bowel obstruction due to irremovable colon cancer.
Ann R Coll Surg Engl.
2004;
86
99-103
14
Law W L, Choi H K, Chu K W.
Comparison of stenting with emergency surgery as palliative treatment for obstructing primary left-sided colorectal cancer.
Br J Surg.
2003;
90
1429-1433
15
Xinopoulos D, Dimitroulopoulos D, Theodosopoulos T. et al .
Stenting or stoma creation for patients with inoperable malignant colonic obstructions? Results of a study and cost-effectiveness analysis.
Surg Endosc.
2004;
18
421-426
16
Fiori E, Lamazza A, de CA . et al .
Palliative management of malignant rectosigmoidal obstruction. Colostomy vs. endoscopic stenting: a randomized prospective trial.
Anticancer Res.
2004;
24
265-268
17
Carne P W, Frye J N, Robertson G M, Frizelle F A.
Stents or open operation for palliation of colorectal cancer: a retrospective, cohort study of perioperative outcome and long-term survival.
Dis Colon Rectum.
2004;
47
1455-1461
18
Hurwitz H, Fehrenbacher L, Novotny W. et al .
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
N Engl J Med.
2004;
350
2335-2342
19
Kabbinavar F F, Schulz J, McCleod M. et al .
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
J Clin Oncol.
2005;
23
3697-3705
20
Karoui M, Charachon A, Delbaldo C. et al .
Stents for palliation of obstructive metastatic colon cancer: impact on management and chemotherapy administration.
Arch Surg.
2007;
142
619-623
21
Aaronson N K, Ahmedzai S, Bergman B. et al .
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.
J Natl Cancer Inst.
1993;
85
365-376
22
Lamers L M, McDonnell J, Stalmeier P F. et al .
The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies.
Health Econ.
2006;
15
1121-1132
23
van Hooft J E, Fockens P, Marinelli A W. et al .
Premature closure of the Dutch Stent-in I study.
Lancet.
2006;
368
1573-1574
24
Athreya S, Moss J, Urquhart G. et al .
Colorectal stenting for colonic obstruction: the indications, complications, effectiveness and outcome: 5-year review.
Eur J Radiol.
2006;
60
91-94
25
Suzuki N, Saunders B P, Thomas-Gibson S. et al .
Colorectal stenting for malignant and benign disease: outcomes in colorectal stenting.
Dis Colon Rectum.
2004;
47
1201-1207
26
Duda S H, Wiskirchen J, Tepe G. et al .
Physical properties of endovascular stents: an experimental comparison.
J Vasc Interv Radiol.
2000;
11
645-654
27
Dyet J F, Watts W G, Ettles D F, Nicholson A A.
Mechanical properties of metallic stents: how do these properties influence the choice of stent for specific lesions?.
Cardiovasc Intervent Radiol.
2000;
23
47-54
28
Stoeckel D, Pelton A, Duerig T.
Self-expanding nitinol stents: material and design considerations.
Eur Radiol.
2004;
14
292-301
29
Palliative chemotherapy for advanced or metastatic colorectal cancer. Colorectal Meta-analysis Collaboration.
Cochrane Database Syst Rev.
2000;
CD001545
30
Costi R, Mazzeo A, di MD . et al .
Palliative resection of colorectal cancer: does it prolong survival?.
Ann Surg Oncol.
2007;
14
2567-2576
31
Konyalian V R, Rosing D K, Haukoos J S. et al .
The role of primary tumour resection in patients with stage IV colorectal cancer.
Colorectal Dis.
2007;
9
430-437
32
Kuo L J, Leu S Y, Liu M C. et al .
How aggressive should we be in patients with stage IV colorectal cancer?.
Dis Colon Rectum.
2003;
46
1646-1652
33
Liu S K, Church J M, Lavery I C, Fazio V W.
Operation in patients with incurable colon cancer: is it worthwhile?.
Dis Colon Rectum.
1997;
40
11-14
34
Ruo L, Gougoutas C, Paty P B. et al .
Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients.
J Am Coll Surg.
2003;
196
722-728
35
Tekkis P P, Poloniecki J D, Thompson M R, Stamatakis J D.
Operative mortality in colorectal cancer: prospective national study.
BMJ.
2003;
327
1196-1201
36
Targownik L E, Spiegel B M, Sack J. et al .
Colonic stent vs. emergency surgery for management of acute left-sided malignant colonic obstruction: a decision analysis.
Gastrointest Endosc.
2004;
60
865-874
1 See Appendix
W. A. Bemelman, MD, PhD
Academic Medical Center Department of Surgery
Meibergdreef 9 1105 AZ Amsterdam The Netherlands
Fax: +31-206914858
Email: W.A.Bemelman@amc.nl